Biofourmis Exit Candidate
π¦ Potential exit path:
SPAC, M&A
Biofourmis is developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. The company's Biovitals (FDA-cleared) AI-powered health analytics platform is made to predict clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics' product pipeline across multiple therapeutic areas — including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.
Select partners: Novartis, Chugai Pharmaceutical, ImagineMIC, Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI).
Funding π°
Total $143.6M
Select investors SoftBank Vision Fund, Sequoia Capital, Openspace Ventures, EDBI, Aviva Ventures
Key people π§βπ€βπ§
- Kuldeep Singh Rajput - Founder & CEO
- Wendou Mark Niu, PhD - Co-founder & Chief Privacy Officer
- Jaydev Thakkar - COO
- Milan Shah - CTO
- Matt Borowiecki - CFO
Highlights β
- Made two acquisitions in the past: Gaido Health from Takeda Pharmaceuticals (April 2020 - to expand in the oncology space) and Switzerland-based Biovotion AG (November 2019 - developer of a clinical-grade wearable biosensor platform)
- Biofourmis' BiovitalsHF solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the FDA π
- The company's AI-enabled remote monitoring platform has been tested with COVID-19 patients in Singapore and Hong Kong π
- As of May 2020, Biofourmis got a new CFO - Matt Borowiecki, who has a decade of experience in investment banking (preparing to go public?) π
- Also, could be an attractive M&A target for Big Pharma or a bigger digital therapeutics company
- Similar companies: Better Therapeutics, Pear Therapeutics
Last update: September 6, 2021
Disclaimer: We can not guarantee that the information on this page is 100% correct. more